Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CACNA2D1 | P54289 | 9/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3856709 | 1.00 | OPRM1 (0.50) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| SCHEMBL3856955 | 1.00 | OPRM1 (0.50) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| SCHEMBL29881540 | 1.00 | OPRM1 (0.50) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| Ammonia Solution, Strong SCHEMBL17473691 | 0.98 | OPRM1 (0.48) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| SCHEMBL4708786 | 0.93 | OPRM1 (0.54) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| SCHEMBL8995127 | 0.91 | OPRM1 (0.52) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| SCHEMBL21307765 | 0.89 | OPRM1 (0.50) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| Octodrine SCHEMBL8343075 | 0.88 | OPRM1 (0.40) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| SCHEMBL18283422 | 0.85 | OPRM1 (0.41) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 | |
| SCHEMBL5787559 | 0.85 | OPRM1 (0.41) | OPRM1PLA2G1BPLA2G2ASIGMAR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1941 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894447-B1 | STABILISERS FOR USE IN INVERSE EMULSION POLYMERISATION PROCESSES | SOLENIS TECHNOLOGIES CAYMAN LP (KY) | 2025-08-13 | — | — | EP | claimed |
| US-20250114479-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | INSTITUTE OF PROCESS ENGINEERING , CHINESE ACADEMY OF SCIENCES (CN) | 2025-04-10 | — | — | US | claimed |
| US-12234303-B2 | Stabilisers for use in inverse emulsion polymerisation processes | SOLENIS TECHNOLOGIES, L.P. (US) | 2025-02-25 | — | — | US | claimed |
| CN-119264359-A | Polyurethane ink resin and preparation method and application thereof | 万华化学（北京）有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-119039220-A | Synthesis method of chloroquine | 上海应用技术大学 | 2024-11-29 | — | — | CN | claimed |
| CN-118638389-A | Shape memory composite material and preparation method and application thereof | 中国科学院兰州化学物理研究所 | 2024-09-13 | — | — | CN | claimed |
| WO-2024183010-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | 中国科学院过程工程研究所 | 2024-09-12 | — | — | WO | claimed |
| CN-117479964-A | Tissue-selective single-component mRNA delivery vector and delivery system | 中国科学院过程工程研究所 | 2024-01-30 | — | — | CN | claimed |
| CN-116769201-A | Poly (chlorotrifluoroethylene) film, preparation method and application thereof | 天津海龙津阳材料科技有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-116715602-A | Fluorenyl oxalyl diamine compound, derivative and application thereof | 华东理工大学 | 2023-09-08 | — | — | CN | claimed |
| US-5821383-A | ESTERIFICATION OF (METH)ACRYLIC ACID WITH ALCOHOL IN PRESENCE OF AN AMINE | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-13 | — | — | US | claimed |
| EP-0858995-A1 | Process for the preparation of N-alkyl carbazoles | Clariant GmbH (DE) | 1998-08-19 | — | — | EP | claimed |
| EP-0512423-B1 | Aqueous solutions of cationic polyamidoamine resins | HOECHST AG (DE) | 1998-07-22 | — | — | EP | claimed |
| EP-0825202-A2 | Process for preparing polymer compositions containing both acid and amine functionality | ROHM AND HAAS COMPANY (US) | 1998-02-25 | — | — | EP | claimed |
| US-5652318-A | USING A MIXTURE OF HARDENERS, ONE OF WHICH IS A POLYOXYALKYLENE GLYCOL ENDCAPPED WITH AMINO GROUPS AND CONTAINING URETHANE GROUPS | HUELS AKTIENGESELLSCHAFT (DE) | 1997-07-29 | — | — | US | claimed |
| EP-0775687-A1 | Process for the preparation of esters of (meth)acrylic acid | BASF AKTIENGESELLSCHAFT (DE) | 1997-05-28 | — | — | EP | claimed |
| EP-0748845-A1 | Process for production of flexible epoxy-resin systems | HÜLS AKTIENGESELLSCHAFT (DE) | 1996-12-18 | — | — | EP | claimed |
| EP-0056766-B1 | PROCESS FOR THE PREPARATION OF 4-AMINO-CHLOROQUINOLINES | RHONE-POULENC SANTE (FR) | 1984-05-16 | — | — | EP | claimed |
| US-4421920-A | AMINATION, AROMATIZATION, RUTHENIUM CATALYST | RHONE-POULENC SANTE (FR) | 1983-12-20 | — | — | US | claimed |
| US-4418201-A | HALIDE LEWIS ACID CATALYST | THE DOW CHEMICAL COMPANY (US) | 1983-11-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114479-A1 | TISSUE-SELECTIVE SINGLE-COMPONENT MRNA DELIVERY CARRIER AND DELIVERY SYSTEM | SLC43A1, LNPEP, TLR3 | OPRM1 390/4885PLA2G1B 2943/4885PLA2G2A 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.